Boehringer Ingelheim Pharm., Inc. v. Fed. Trade Comm'n
136 S. Ct. 925, 193 L. Ed. 2d 790, 84 U.S.L.W. 3405, 2016 U.S. LEXIS 692
Supreme Court of the United States·Decided January 19, 2016·No. No. 15–560.·Published·Cited by 1 cases
Opinion
Petition for writ of certiorari to the United States Court of Appeals for the District of Columbia Circuit denied.
Free access — add to your briefcase to read the full text and ask questions with AI
Boehringer Ingelheim Pharm., Inc. v. Fed. Trade Comm'n, 136 S. Ct. 925, 193 L. Ed. 2d 790, 84 U.S.L.W. 3405, 2016 U.S. LEXIS 692 (U.S. 2016).
136 S. Ct. 925 (Boehringer Ingelheim Pharm., Inc. v. Fed. Trade Comm'n) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.
Related
Federal Trade Commission v. Boehringer Ingelheim Pharmaceuticals, Inc.
241 F. Supp. 3d 91 (District of Columbia, 2017)